Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2023-07-10 Director's Dealing
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2023-07-10 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 1% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the completion of a specific asset transfer (divestiture of investment fund shares) by InnoTherapy. While the title mentions 'merger', the content specifically describes an asset disposal transaction. Since this is a formal regulatory filing regarding a corporate transaction (M&A/Asset disposal) and does not fit into the other specific categories like 'TAR' (which is usually for proposals/bids) or 'RPA' (which is for announcements of reports), it is best classified as a Regulatory Filing (RNS) as it is a mandatory disclosure of a completed corporate event.
2023-06-30 Korean
주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to dispose of shares in another corporation (타법인 주식 및 출자증권 양도결정). This type of regulatory filing in the Korean market is a mandatory disclosure of significant corporate events, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to company-wide takeovers) or other specialized reports.
2023-06-26 Korean
타법인주식및출자증권취득결정(자율공시)
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) regarding the acquisition of shares in another company (PhAST Corp.). This type of disclosure, specifically labeled as '타법인주식및출자증권취득결정' (Decision to acquire shares/securities of another corporation), is a standard corporate event announcement. Since it does not fit into specific categories like M&A (which usually implies a merger or takeover of the entity itself) or capital changes (which usually refers to the company's own shares), it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2023-06-09 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'InnoTherapy' (주식회사 이노테라피) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial data, business operations, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the acquisition of convertible bonds before maturity (Put Option exercise). This falls under capital structure changes and financing activities, specifically related to debt instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate classification for announcements regarding the redemption or acquisition of convertible bonds.
2023-05-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.